AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Discover the strategic reasons ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of North Carolina's largest ...

Biogen Inc. intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing ...

(RTTNews) - Biogen Inc. (BIIB) said it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. In the next few years, Biogen ...

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date In the next few years, Biogen plans to continue investing in multiple ...

July 21 (Reuters) - Biogen (BIIB.O), opens new tab will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as it seeks to expand in the U.S.

Contract drug manufacturer Patheon has named former chief executive of Biogen Idec to be the company’s new CEO. James Mullen’s appointment to lead Patheon (TSX:PTI), based in North Carolina’s Research ...

Biogen employees work inside a lab used to produce cell cultures in 2014 at the firm’s Research Triangle Park facilities. N&O file photo Biogen commits $2 billion to expand RTP campuses in Wake and ...

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: ...

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as it seeks to expand in the U.S. amid President Donald Trump's tariff threats.